KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis. PMID 40155828 · BMC Cancer · 2025-Mar-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. PMID 40132102 · Europace · 2025-Mar-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Missing Mechanism of Effect: How People Who Habitually Replot Stories React Differently (Or Not so Differently) to Melanoma Narratives. PMID 39550610 · J Health Commun · 2025-Mar-28 While the study is an oncology-related randomized trial in humans, it is excluded because it is not a drug intervention trial and does not have a primary time-to-event efficacy endpoint. The outcome measured is behavioral intention, not survival or progression metrics.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracKing - protocol of a non-randomised, open-label, single-arm, phase II study. PMID 40147985 · BMJ Open · 2025-Mar-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association of energy source with outcomes in en bloc TURB: secondary analysis of a randomized trial. PMID 40146341 · World J Urol · 2025-Mar-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. PMID 40106374 · N Engl J Med · 2025-Mar-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Inebilizumab for Treatment of IgG4-Related Disease. PMID 39541094 · N Engl J Med · 2025-Mar-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinical experience with cryopreserved mesenchymal stem cells for cardiovascular applications: A systematic review. PMID 40160690 · World J Stem Cells · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial. PMID 40140821 · Mol Cancer · 2025-Mar-26 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (iDFS), but the trial phase is not specified in the provided metadata as Phase III/IIIb or Phase II/III. Furthermore, the primary endpoint is pCR (a binary endpoint), while iDFS is a secondary endpoint. To be eligible, the trial must be Phase III/IIIb or Phase II/III and must have a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. PMID 40139834 · J Immunother Cancer · 2025-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis. PMID 40137838 · Clin J Am Soc Nephrol · 2025-Mar-26 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. PMID 40135712 · Cochrane Database Syst Rev · 2025-Mar-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study. PMID 40010134 · Eur J Cancer · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study. PMID 39999670 · Eur J Cancer · 2025-Mar-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial. PMID 40133484 · NPJ Precis Oncol · 2025-Mar-25 The study is a randomized clinical trial in oncology (ovarian cancer) with a drug intervention (chemotherapy) and reports time-to-event endpoints (PFS with HR). However, the abstract explicitly states the primary outcome was Objective Response Rate (ORR), which is not a time-to-event endpoint. The phase (III/IIIb or II/III) is not clearly established in the provided metadata. Therefore, it does not meet all required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment group-specific inferences in Phase III Randomized Oncology Trials. PMID 40126209 · Acta Oncol · 2025-Mar-24 This is a methodological review analyzing 774 published Phase III oncology trials, not the original result report of a single randomized trial. It lacks a specific drug intervention and does not present a primary time-to-event efficacy endpoint for a single study.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer. PMID 40123110 · Med Sci Monit · 2025-Mar-24 The study is a randomized, oncology, human trial with a drug intervention (cholecalciferol). However, it is not a Phase III trial, and the primary outcome is a categorical response rate (complete response), not a time-to-event endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. Therefore, it does not meet the eligibility criteria for a KM-digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19. PMID 40278658 · Toxins (Basel) · 2025-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial. PMID 40122906 · Nat Commun · 2025-Mar-23 The study is a Phase III randomized trial in oncology with time-to-event endpoints, but it fails the core criterion of having a drug-containing intervention as the primary efficacy focus. The drug (ulinastatin) is used to prevent/treat a toxicity (oral mucositis) of radiotherapy, not as an anti-cancer therapy. The primary endpoint is a toxicity/incidence endpoint, not a time-to-event efficacy endpoint. The reported survival outcomes are secondary and show no significant difference, indicating the drug is not being evaluated for its anti-tumor efficacy. Therefore, it does not meet the requirement for a drug intervention trial with a primary/key secondary time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the impact of a self-guided digital intervention for fear of cancer recurrence (iConquerFear) in ovarian cancer survivors: a pilot randomised waitlist-controlled trial. PMID 40122804 · BMC Cancer · 2025-Mar-23 The record describes a pilot randomized trial of a digital intervention for fear of cancer recurrence. It is not Phase III/IIIb or Phase II/III, lacks a drug intervention, and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10). PMID 40333240 · Vaccines (Basel) · 2025-Mar-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. PMID 40121452 · Cardiovasc Diabetol · 2025-Mar-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. PMID 40121197 · Nat Commun · 2025-Mar-22 The report is a preplanned biomarker subgroup analysis of a phase 3 randomized trial, not the primary formal-result report of the trial's overall efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pharmacological Monotherapy for Depressive Disorders: Current and Future-A Narrative Review. PMID 40282849 · Medicina (Kaunas) · 2025-Mar-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results. PMID 40009739 · Dtsch Arztebl Int · 2025-Mar-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. PMID 39889250 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. PMID 39693584 · J Clin Oncol · 2025-Mar-20 The report is a Phase III randomized oncology trial with a time-to-event efficacy endpoint, but it does not involve a drug-containing intervention, comparing only non-drug local therapies.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). PMID 39680823 · J Clin Oncol · 2025-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: study protocol for a phase 3 randomised double-blind placebo-controlled trial (NIPP-RD III). PMID 40108640 · Trials · 2025-Mar-19 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone. PMID 40108635 · Breast Cancer Res · 2025-Mar-19 This report is a biomarker subgroup analysis of a randomized trial, not the primary result report of a definitive Phase III/IIIb or Phase II/III trial. The trial phase is not explicitly established in the provided metadata as meeting the required threshold.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sonolysis during carotid endarterectomy: randomised controlled trial. PMID 40107675 · BMJ · 2025-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. PMID 40105996 · J Neurol · 2025-Mar-19 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. PMID 40102973 · Trials · 2025-Mar-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial. PMID 39923547 · Vaccine · 2025-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. PMID 39919447 · Vaccine · 2025-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Is it beneficial to add laser ablation to curettage in the treatment of pilonidal sinus disease? PMID 40100423 · Lasers Med Sci · 2025-Mar-18 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study. PMID 40096297 · Circulation · 2025-Mar-18 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy. PMID 40074465 · J Am Coll Cardiol · 2025-Mar-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. PMID 39708367 · Br J Dermatol · 2025-Mar-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. PMID 39665585 · JAMA · 2025-Mar-18 The trial meets oncology, human, randomized, and time-to-event criteria but is excluded because the intervention is non-drug-only (active monitoring vs. surgery/radiation) and the Phase III/IIIb or Phase II/III status is not explicitly established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. PMID 39611771 · Br J Dermatol · 2025-Mar-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J). PMID 39442013 · Br J Dermatol · 2025-Mar-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study. PMID 40098083 · BMC Cancer · 2025-Mar-17 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original results. However, the primary and secondary endpoints (duration of neutropenia, incidence of febrile neutropenia) are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.) and do not involve Kaplan-Meier analysis or hazard ratios. The study evaluates supportive care efficacy (neutropenia management) in an oncology population, which is excluded from the cohort's scope.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Suppressive effects of deep balanced anesthesia on cellular immunity and protein expression: a randomized-controlled pilot study. PMID 40097954 · BMC Anesthesiol · 2025-Mar-17 Study is a randomized pilot study on anesthesia effects on immune function, not an oncology drug trial with time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). PMID 39836408 · Clin Cancer Res · 2025-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial. PMID 39836372 · Clin Cancer Res · 2025-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. PMID 39820657 · Clin Cancer Res · 2025-Mar-17 This is a biomarker correlative study from two randomized Phase II trials (STOMP and ORIOLE) evaluating stereotactic ablative radiotherapy (SABR), not a drug-containing intervention. The primary analysis is biomarker-focused and does not represent the original primary efficacy report of the trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials. PMID 39587780 · Aesthet Surg J · 2025-Mar-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. PMID 39376010 · J Clin Endocrinol Metab · 2025-Mar-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. PMID 39302855 · J Infect Dis · 2025-Mar-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -